In their study, Malfitano et al. (Malfitano et al., 2020) reported that treatment with vascular endothelial growth factor (VEGF) can modulate the release of cytokines, including IL-1β, IL-6, and CXCL1, thereby disrupting the immune homeostasis of the tumor microenvironment and creating an environment conducive to immune-based therapies. Here, VEGFA is linked to neoplasm.